The development of tools for evaluating new immunotherapies based on induction of CD8+ cytotoxic T lymphocytes, specifically those that can recognize tumor-specific Ags such as neoepitopes, could be useful to accelerate RCC research. Here, CD8A is linked to neoplasm.